Perspective
Volume 08:06, 2024

Virology: Current Research

ISSN: 2736-657X

Open Access

Revealing Polymorphism: Examining Its Contribution to Symptomatic COVID-19 Risk

Vihaan Gupta*

Department of Infectious Diseases, SCB Medical College & Hospital, Cuttack, India

Introduction

The COVID-19 pandemic, caused by the virus, has dramatically altered the global landscape, with millions of infections and significant mortality. While many individuals infected with remain asymptomatic or experience mild symptoms, others develop severe or even fatal illness. This disparity in disease severity has spurred significant scientific inquiry into the factors that influence the development of symptomatic COVID-19. One critical area of research has focused on genetic polymorphisms—the variation in DNA sequences that occur naturally within populations and contribute to individual differences in health outcomes. These genetic variations have the potential to explain why some people develop severe symptoms upon infection with, while others experience mild or no symptoms. In this article, we explore the role of polymorphisms in determining the risk of symptomatic COVID-19, shedding light on how genetic differences can influence immune responses and disease progression. Polymorphism refers to the occurrence of different genetic variants within a population. These variations can occur in coding or non-coding regions of genes, and they can affect various biological processes. Some polymorphisms may have little or no impact on an individual's health, while others can play a significant role in susceptibility to diseases, including infections. In the context of COVID-19, polymorphisms can influence an individual's immune system, receptor interactions, inflammatory responses, and other mechanisms involved in disease susceptibility [1-3].

Description

When SARS-CoV-2 infects a person, the immune system mounts a defense to fight the virus. The severity of COVID-19 is influenced by the efficiency and appropriateness of this immune response. However, the immune response can vary significantly between individuals due to genetic differences, which can impact the severity of the disease. Polymorphisms in genes that influence immune responses such as those involved in inflammation, antigen presentation, and T-cell activation are crucial in determining how well a person can fight the virus. Some polymorphisms may predispose an individual to an overactive immune response. Immune system functions by presenting viral antigens to T-cells, which help the body mount an adaptive immune response. HLA polymorphisms, particularly those in the HLA-B and HLA-C loci, have been shown to influence the immune response to viral infections, including. Some individuals carry alleles that enhance the presentation of antigens, leading to a more robust immune response and a better ability to clear the virus. Conversely, other polymorphisms may impair immune recognition, potentially increasing susceptibility to more severe disease [4,5].

Conclusion

The role of genetic polymorphisms in determining the risk of symptomatic COVID-19 is a rapidly evolving area of research. Variations in genes that influence immune responses, viral entry, and inflammation can significantly affect disease severity. As research continues, a deeper understanding of these genetic factors will not only help identify those at higher risk but may also lead to personalized therapeutic and preventive strategies for COVID-19. Ultimately, unlocking the mysteries of polymorphism in the context of COVID-19 will pave the way for more effective treatments and better outcomes for patients around the world. Understanding the contribution of genetic polymorphisms to symptomatic COVID-19 risk has important implications for public health and treatment strategies. Genetic screening could be used to identify individuals at higher risk of severe disease, allowing for targeted interventions such as early antiviral treatments or personalized vaccination strategies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Alanazi, Saad Awadh, M. M. Kamruzzaman, Madallah Alruwaili and Nasser Alshammari, et al. "Measuring and preventing COVID-19 using the SIR model and machine learning in smart health care." *J Health Eng* 2020 (2020).
2. Hussein, Haval I., Abdulhakeem O. Mohammed, Masoud M. Hassan and Ramadhan J. Mstafa. "Lightweight deep CNN-based models for early detection of COVID-19 patients from chest X-ray images." *Exp Syst Appl* 223 (2023): 119900.
3. Rahimi, Iman, Fang Chen and Amir H. Gandomi. "A review on COVID-19 forecasting models." *Neural Comput Appl* 35 (2023): 23671-23681.
4. Lakdawalla, Darius N., Jalpa A. Doshi, Louis P. Garrison Jr. and Charles E. Phelps, et al. "Defining elements of value in health care—a health economics approach: An ISPOR Special Task Force report [3]." *Value Health* 21 (2018): 131-139.
5. Bowe, Benjamin, Yan Xie and Ziyad Al-Aly. "Postacute sequelae of COVID-19 at 2 years." *Nat Med* 29 (2023): 2347-2357.

***Address for Correspondence:** Vihaan D. Gupta, Department of Infectious Diseases, SCB Medical College & Hospital, Cuttack, India; E-mail: guptav@gmail.com*

Received: 02 November, 2024, Manuscript No. vcrh-25-157208; **Editor Assigned:** 04 November, 2024, PreQC No. P-157208; **Reviewed:** 16 November, 2024, QC No. Q-157208; **Revised:** 23 November, 2024, Manuscript No. R-157208; **Published:** 30 November, 2024, DOI: 10.37421/2736-657X.2024.8.280

How to cite this article: Gupta, Vihaan. "Revealing Polymorphism: Examining Its Contribution to Symptomatic COVID-19 Risk." *Virol Curr Res* 8 (2024): 280.